Shortage of BICILLIN L-A benzathine benzylpenicillin tetrahydrate 1,200,000 Units / 2.3 mL suspension for injection pre-filled syringe with needle (AUST R: 147169)

2 hours ago
1 min read

Dear Healthcare Professional,

Shortage of BICILLIN L-A benzathine benzylpenicillin tetrahydrate 1,200,000 Units / 2.3 mL suspension for injection pre-filled syringe with needle (AUST R: 147169) and alternative supply arrangement under section 19A of the Therapeutic Goods Act 1989

Pro Pharmaceuticals Group recognises the importance of supplying essential medicines in Australia and would like to advise you the change in supply status of BICILLIN L-A benzathine benzylpenicillin tetrahydrate 1,200,000 Units / 2.3 mL suspension for injection pre-filled syringe with needle (AUST R: 147169) in Australia.

The Australian registered medicine, BICILLIN L-A benzathine benzylpenicillin tetrahydrate 1,200,000 Units / 2.3 mL suspension for injection pre-filled syringe with needle (AUST R: 147169) sponsored by Pfizer Australia Pty Ltd is currently in shortage due to manufacturing issues.

Pro Pharmaceuticals Group has arranged for the supply of an alternative product, Benzylpenicillin benzathine 1.2 million I.U powder for suspension for injection (Brancaster Pharma, UK), on a temporary basis . This product is NOT registered in Australia and supply is authorised under an exemption granted by the Therapeutic Goods Administration (TGA) under section 19A of the Therapeutic Goods Act 1989 until 31st January 2027.

For detailed information, including administration instructions and a comparison with the ARTG-listed product, please refer to the Dear Healthcare Professional (DHCP) letter approved by the TGA.

For orders or further information:

For any regulatory or pharmacovigilance enquiries, please contact: regulatory@propg.com.au

Please circulate this information to the relevant teams within your organisation.